Seelos therapeutics announces the close of enrollment of its registration directed study of sls-002 (intranasal racemic ketamine) for acute suicidal ideation and behavior (asib) in adults with major depressive disorder (mdd)

- there is currently no fda approved treatment for asib in mdd. - top-line data from this study is expected in the third quarter of 2023.
SEEL Ratings Summary
SEEL Quant Ranking